CVS Health Corporation CVS
Verdict: Sell. Fair value $67.19 against a price of $80.42 on 6 Jan 2026, 16% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Operating Cash Flow has declined precipitously from $18.27B in 2021 to $9.11B in 2024, a 50% drop..... Net Income exhibits extreme volatility ($8.0B in 2021, $4.3B in 2022, $8.3B in 2023, $4.6B in 2024)....
Main risks
- Collapsing Profitability & Cash Flow: FCF margin has plummeted from 5.4% in 2021 to 1.6% TTM, and net margin has more than halved over the same period, indicating a severe erosion of profitability.
- Extremely Poor Capital Allocation: ROE is a low 6.1% and the estimated 3-year ROIIC is alarmingly negative (-117.1%), suggesting recent capital investments have destroyed significant shareholder value.
- High Financial Leverage: The estimated Net Debt/EBITDA ratio is a concerning ~9.1x, which is very high and poses significant financial risk, especially in the context of declining profitability.
- Operating Cash Flow has declined precipitously from $18.27B in 2021 to $9.11B in 2024, a 50% drop....
- Net Income exhibits extreme volatility ($8.0B in 2021, $4.3B in 2022, $8.3B in 2023, $4.6B in 2024)...
- Intense competitive environment